VAP

Responsible Solar: First Solar Leads Industry with Validated Environmental and Social Performance and Transparent Reporting

Retrieved on: 
Monday, September 9, 2024
Other Manufacturing, Environment, Professional Services, Manufacturing, Alternative Energy, Sustainability, Energy, Environmental, Social and Governance (ESG), Recycling, Risk, Marketing, Steel, Business, RBA, FSLR, Electricity, Carbon, Coal, VAP, First Solar, Aluminium, Glass, Research, Climate change, Cadmium telluride, TR1, PV, EPEAT, Renewable energy

According to its 2024 Sustainability Report , which was released today, First Solar , Inc. (Nasdaq: FSLR) has established new industry benchmarks including verifiable leadership in ultra low-carbon solar technology, high-value recycling, respect for human rights, and transparent reporting.

Key Points: 
  • According to its 2024 Sustainability Report , which was released today, First Solar , Inc. (Nasdaq: FSLR) has established new industry benchmarks including verifiable leadership in ultra low-carbon solar technology, high-value recycling, respect for human rights, and transparent reporting.
  • Headquartered in the United States, First Solar is the largest solar manufacturer in the Western Hemisphere and the world’s largest high-value solar panel recycler.
  • “The results of building our company on a principled foundation are apparent from our verifiable leadership in environmental and social performance and reporting.
  • Not reliant on Chinese crystalline silicon supply chains, First Solar does not source materials from Xinjiang, China.

Genus plc Preliminary Results for the Year Ended 30 June 2024

Retrieved on: 
Thursday, September 5, 2024
Health, Genetics, Agriculture, Natural Resources, Research, Science, Biotechnology, PBT, Growth, Investment, ABS, VAP, Pharmaceutical industry

Compares with first half adjusted operating profit including JVs of £38.1m, 17% lower year on year in constant currency

Key Points: 
  • Compares with first half adjusted operating profit including JVs of £38.1m, 17% lower year on year in constant currency
    Adjusted profit before tax (PBT) of £59.8m, 8%2 lower in constant currency (16% lower in actual currency).
  • These APMs should be considered in addition to statutory measures, and not as a substitute for or as superior to them.
  • 6 Free cash flow definition has changed this year to include lease repayments, the 2023 comparative has also been restated
    7 Prior year period restated.
  • 8 Net exceptional expenses of £24.6m predominantly comprised £10.4m related to ST litigation and settlements, £6.7m related to restructuring activity and £7.4m related to a number of potential corporate transactions which are no longer active

Universal Electronics Inc. Successfully Completes RBA VAP Audit

Retrieved on: 
Wednesday, August 14, 2024
Technology, Mobile, Wireless, Construction & Property, Professional Services, Building Systems, Hardware, Environmental, Social and Governance (ESG), IOT (Internet of Things), Consumer Electronics, Certification, Environment, Universal Electronics, Health, UEI, Safety, Ethics, RBA, Occupational safety and health, VAP

Universal Electronics Inc. (UEI) (NASDAQ: UEIC), the global leader in universal control solutions for the home, announced today that it successfully completed the Responsible Business Alliance (RBA) Validated Assessment Program (VAP) audit at its facility in Vietnam (UVN).

Key Points: 
  • Universal Electronics Inc. (UEI) (NASDAQ: UEIC), the global leader in universal control solutions for the home, announced today that it successfully completed the Responsible Business Alliance (RBA) Validated Assessment Program (VAP) audit at its facility in Vietnam (UVN).
  • UEI’s score indicates that its UVN facility has met the RBA VAP audit criteria and demonstrates a high level of compliance with the RBA Code of Conduct.
  • This audit affirms our dedication to operating ethically and responsibly across our global footprint,” said Paul Arling, Chairman and CEO of UEI.
  • For more information about the RBA and its VAP program, please visit [ https://www.responsiblebusiness.org/ ].

Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter baumannii

Retrieved on: 
Wednesday, July 10, 2024
RCE, Urinary tract infection, Meningitis, VAP, ABSSSI, UTI, Bacteria, Patient, Mortality, Murdoch, WHO, Infection, World Health Organization, Acinetobacter baumannii, Escherichia coli, Phase, Ciprofloxacin, Ventilator-associated pneumonia, Safety, ASX, Cell, AIR, MDR, Pharmaceutical industry

“These outstanding results highlight the potent efficacy of R327 in combating MDR bacteria, a significant global health challenge,” commented James Graham, CEO of Recce Pharmaceuticals.

Key Points: 
  • “These outstanding results highlight the potent efficacy of R327 in combating MDR bacteria, a significant global health challenge,” commented James Graham, CEO of Recce Pharmaceuticals.
  • The sustained efficacy of R327 compared to ciprofloxacin underscores its potential as a superior treatment option.
  • The WHO has listed A. baumannii as one of the top priority pathogens due to its high levels of resistance to multiple antibiotics.
  • The demonstrated efficacy against MDR A. baumannii further builds out the efficacy profile of R327 against UTI-causing pathogens and will support the initiation of a Phase II trial in patients with UTI/Urosepsis.

Viromed Medical AG Seeks Special Approval for Cold Plasma Device for the Prevention of Ventilator-Associated Pneumonia (VAP)

Retrieved on: 
Wednesday, July 10, 2024
Health, Medical Devices, Health Technology, Research, Science, Pharmaceutical, Biotechnology, TDK Electronics, Electronics, Hannover Medical School, Medicine, VAP, Cell death, Infection, Epithelium, Gesellschaft mit beschränkter Haftung, Patient, Mortality, Cell damage, Lung, Pulmonology, Simple squamous epithelium, MHH, Ventilator-associated pneumonia, Plasma, DNA, Death, Safety, Differentiable function, DNA repair, Ventilator, Medical device

Viromed Medical AG (ISIN: DE000A3MQR65; "Viromed") is launching a second pioneering study on the use of cold plasma for the prevention of ventilator-associated pneumonia (VAP).

Key Points: 
  • Viromed Medical AG (ISIN: DE000A3MQR65; "Viromed") is launching a second pioneering study on the use of cold plasma for the prevention of ventilator-associated pneumonia (VAP).
  • As a partner of Viromed, relyon plasma will establish the prototypes for the application and ensure the standardized generation of cold plasma as well as its characterization and consistency in the trial.
  • Uwe Perbandt, CEO of Viromed Medical AG: "The use of cold plasma has already proven very successful in the treatment of difficult-to-heal wounds.
  • In particular, the focus is on the potential of cold plasma to kill bacteria that have infected the epithelium.

EQS-News: Viromed Medical AG seeks special approval for cold plasma device for the prevention of ventilator-associated pneumonia (VAP)

Retrieved on: 
Wednesday, July 10, 2024
TDK Electronics, Electronics, Hannover Medical School, VAP, Cell death, Infection, Epithelium, Gesellschaft mit beschränkter Haftung, Patient, Mortality, Cell damage, Lung, Pulmonology, Simple squamous epithelium, MHH, Research, Ventilator-associated pneumonia, Plasma, DNA, Death, Safety, Differentiable function, DNA repair, Ventilator, Medical device

Pinneberg, 10 July 2024 – Viromed Medical AG (ISIN: DE000A3MQR65; "Viromed") is launching a second pioneering study on the use of cold plasma for the prevention of ventilator-associated pneumonia (VAP).

Key Points: 
  • Pinneberg, 10 July 2024 – Viromed Medical AG (ISIN: DE000A3MQR65; "Viromed") is launching a second pioneering study on the use of cold plasma for the prevention of ventilator-associated pneumonia (VAP).
  • As a partner of Viromed, relyon plasma will establish the prototypes for the application and ensure the standardized generation of cold plasma as well as its characterization and consistency in the trial.
  • Uwe Perbandt, CEO of Viromed Medical AG: "The use of cold plasma has already proven very successful in the treatment of difficult-to-heal wounds.
  • In particular, the focus is on the potential of cold plasma to kill bacteria that have infected the epithelium.

Aridis Provides Corporate Update

Retrieved on: 
Monday, June 24, 2024
Bronchopneumonia, Investment, EMA, LOS, FDA, COVID-19, European Medicines Agency, VAP, Clutch (eggs), Safety, NIH, MedImmune, Clinical trial, Licensure, Cystic fibrosis, Patient, OTC, APEX, Concurrence, Length of stay, ICU, Trial of the century, Pharmaceutical industry

LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent developments.

Key Points: 
  • LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent developments.
  • The discussions with potential partners to continue the development of AR-301 are expected to reach a definitive outcome in the 4th quarter.
  • Development status: AR-301 is currently being evaluated for the adjunctive therapeutic treatment of Ventilator Associated Pneumonia (VAP).
  • The Company has been working with its lead lender Streeterville Capital, LLC to service the loan via equity exchange agreements.

Digital Renaissance: Global Market of Artification Brings Rubens and Rembrandt Artworks to Global Blockchain Show

Retrieved on: 
Thursday, April 11, 2024
Ethereum, Gallery, Blockchain, Non-fungible token, VAP, National Gallery, GMA, NFT, ETH, Cryptocurrency

Dubai, April 11, 2024 (GLOBE NEWSWIRE) --  The Global Blockchain Show is pleased to announce Global Market of Artification (GMA) as its diamond sponsor at the upcoming two-day conference, set to take place at the Grand Hyatt, Dubai. Artworks by renowned masters like Rubens and Rembrandt will be featured at the event. With the inclusion of GMA, the event aims to provide a platform for all emerging and established NFT artists to showcase their designs and art.

Key Points: 
  • Artworks by renowned masters like Rubens and Rembrandt will be featured at the event.
  • Rome-based company GMA is focused on offering NFT services through a unique tokenization experience, enabling a new form of investment in world-renowned artworks.
  • The company will bring about 30 digital artworks and five physical pieces from the Renaissance period to the Global Blockchain Show including works of Rembrandt, Rubens, Lorenzo Lotto, Antonio Allegri and many more.
  • Witness some of the world’s most iconic NFT artworks at the Global Blockchain Show, taking place at the Grand Hyatt, Dubai on April 16 and 17.

European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options

Retrieved on: 
Monday, April 22, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Mortality, Urinary tract infection, Pyelonephritis, WHO, News, World Health Organization, Safety, Infection, European Commission, Bacteria, Inc., AMR, Aztreonam, HAP, Fungal infection, VAP, Hospital-acquired pneumonia, Gram-negative bacteria, Patient, PFE, Ventilator-associated pneumonia, Parasitism, Multiple drug resistance, Virus, Civil service commission, Fungus, Antimicrobial resistance, Head, Disease, Gram, Vaccine

(NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.

Key Points: 
  • (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.
  • It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
  • “For healthcare teams treating patients with serious Gram-negative bacterial infections, the prospect of running out of effective treatment options is a daunting but very real threat,” said Yehuda Carmeli, Head, National Institute for Antibiotic Resistance and Infection Control, Tel Aviv Medical Center, Israel, and an investigator in the REVISIT study.
  • Marketing authorization applications for EMBLAVEO are planned for submission in other countries.

Independent Studies Presented at ESCMID Global Demonstrate the Clinical Utility of SeptiCyte® RAPID in Patients Suspected of Sepsis, Including in Polytrauma Patients

Retrieved on: 
Wednesday, April 17, 2024
Infection, Polytrauma, Hospital-acquired infection, Trauma, Internship, Systemic inflammatory response syndrome, Animation, SIRS, VAP, ICU, Ventilator-associated pneumonia, Fungal infection, Patient, University of Nantes, Diagnosis, Sepsis, Pharmaceutical industry

SeptiCyte® RAPID accurately differentiated between nosocomial infections and systemic inflammatory response syndrome in polytrauma ICU patients suspected of sepsis.

Key Points: 
  • SeptiCyte® RAPID accurately differentiated between nosocomial infections and systemic inflammatory response syndrome in polytrauma ICU patients suspected of sepsis.
  • SeptiScore® was elevated in ICU patients suspected of sepsis when a causative pathogen was identified.
  • A Nantes University poster #P3895 entitled, "SeptiCyte RAPID, a new biomarker for the diagnosis of ventilator-associated pneumonia in polytrauma patients," will be presented on April 27, at noon CET.
  • Samples were evaluated using SeptiCyte RAPID and compared to a standard clinical evaluation by a blinded physician in the ICU.